FibroGen (NASDAQ:FGEN) Raised to “Strong-Buy” at HC Wainwright

HC Wainwright upgraded shares of FibroGen (NASDAQ:FGEN) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports. HC Wainwright also issued estimates for FibroGen’s FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

FGEN has been the topic of several other research reports. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. StockNews.com started coverage on shares of FibroGen in a research report on Monday. They set a “hold” rating for the company.

FibroGen Trading Up 7.1 %

FibroGen stock opened at $0.35 on Tuesday. The stock has a 50 day moving average of $0.35 and a 200-day moving average of $0.58. The stock has a market cap of $35.08 million, a P/E ratio of -0.28 and a beta of 0.82. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period in the prior year, the business earned ($0.52) earnings per share. As a group, equities analysts predict that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd raised its stake in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares in the last quarter. Doheny Asset Management CA acquired a new position in FibroGen during the 2nd quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in FibroGen during the second quarter worth approximately $130,000. Sei Investments Co. lifted its holdings in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in FibroGen during the second quarter worth about $145,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.